Wedbush Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $70
Benzinga Newsdesk 7 months ago
NewsPrice TargetInitiationAnalyst Ratings
Wedbush analyst Martin Fan initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Neutral rating and announces Price Target of $70.
Wedbush analyst Martin Fan initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Neutral rating and announces Price Target of $70.